

Press release

APOGEPHA acquired the majority shares of Rocketlane Medical Ventures

December, 2022: APOGEPHA Arzneimittel GmbH proudly announces that it has acquired the majority shares of Rocketlane Medical Ventures GmbH, a start-up company located in Munich that has developed a digital therapeutic for prostate cancer which includes the treatment of incontinence and erectile dysfunction after prostatectomy. The medical product Uroletics® is already CE-certified and reimbursed by selected health insurance funds. It needs to undergo further clinical development for the registration as DiGA in Germany.

This acquisition will broaden APOGEPHA's portfolio in the treatment of urological indications and will be an important step in line with APOGEPHA's strategy to become a Health Provider in the field of urology and uro-oncology.

Rocketlane Medical ventures was founded in 2020 by PD Dr. Jan-Niclas Mumm, MHBA and PD Dr. Severin Rodler, two urologists with special focus on uro-oncology and functional-urology. They both completed their medical training at one of the leading university clinics, LMU in Munich, Germany. We are very happy that we have APOGEPHA as a strategic investor on board to support us in the further development of our digital therapeutic as well as to professionalise the marketing and sales activities of the product, PD Dr. Mumm and PD Dr. Rodler commented.

“This DiGA is addressing high medical needs of prostate cancer patients that have to undergo total prostate resection, since the majority of

patients will suffer from urinary incontinence and erectile dysfunction at least temporarily. The Uroletics® app with modules supporting the patients before and after the surgery will help to take all measures to diminish the probability of such conditions. In addition, the Uroletics® app digitises the entire prostate cancer aftercare process for both doctors and patients. This product has a perfect fit to our existing portfolio in the field of prostate cancer and will leverage our footprint in this indication” Dr. Dirk Pamperin, general manager of APOGEPHA emphasized. Together with our colleagues PD Dr. Mumm and PD Dr. Rodler, we will further invest in the company to develop additional solution for patients with urological and uro-oncological indications, Lisa Kube, Manager Business Development at APOGEPHA added.

The conditions of the acquisition have not been disclosed

About APOGEPHA Arzneimittel GmbH

APOGEPHA Arzneimittel GmbH is a family-owned German pharmaceutical company with about 150 employees and its headquarters in Dresden. The company is specialised in urology an uro-oncology and has long-lasting experience as well as high expertise in in development, marketing, and sales of innovative products. With its highly skilled sales team the company reaches Health Care Professionals with scientific sound information to bring wide treatment options to patients. APOGEPHA’s products are sold in 25 markets worldwide.

For more company information, please visit www.apogepha.com.

About Rocketlane Medical Ventures

Rocketlane Medical Ventures has been developing digital health solutions for a patient-centered digitalization of the healthcare system since 2020. With the Uroletics® app, the company has established the first digital therapy for prostate cancer. The two founders, PD Dr. med. Jan-Niclas Mumm, MHBA and PD Dr. med. Severin Rodler, are both

practicing physicians and incorporate their clinical experience from a university hospital and urological practice into the development of the Rocketlane projects. In cooperation with Apogepha Arzneimittel GmbH, Rocketlane Medical Ventures GmbH is initiating a new era of digital uro-oncological medicine and patient-centered virtual care models. For more company information, please visit www.Uroletics.com

Contact

APOGEPHA Arzneimittel GmbH

Kyffhäuserstraße 27

01309 Dresden

Steffi Liebig

Director Health Policy & Corporate Communication

Tel.: +49-351/33 63 497

Fax: +49-351/33 63 440

E-mail: sliebig@apogepha.de